The first-and-only bispecific antibody given by subcutaneous injection in diffuse large B-cell lymphoma (DLBCL).

Approved to treat adults with certain types of DLBCL and high-grade B-cell lymphoma that has come back or that didn't respond after 2 or more prior treatments.

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.


Use this guide to make the most of your appointment with your healthcare provider to discuss if EPKINLY could be right for you.


Get more information about treatment with EPKINLY.


Support when you need it

Dedicated support is available for you and your care partner. Get help with tracking symptoms, preparing for appointments, talking to your doctor, and finding information about financial support options.

Two women walking outside.

What’s next? Now is the time to make a plan with your doctor.